FDA Approves Two New Treatments for Acute Myeloid Leukemia

This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists treating certain groups of patients with acute myeloid leukemia (AML): enasidenib (Idhifa) and Vyxeos. This news is particularly welcome because AML is the form of leukemia with the lowest five-year relative survival rate.

Read More

Charting the Future of Cancer Health Disparities Research

Yesterday, the American Association for Cancer Research (AACR) joined the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) in releasing a joint position statement to guide the future of cancer health disparities research.

Read More

AACR Blog Turns 3: Check Out Our Top 10 Posts

Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief Executive Officer Margaret Foti, PhD, MD (hc). Since then, we’ve had the privilege of reporting on some significant progress against cancer, including the rise of immunotherapy and precision medicine.

Read More

FDA Approves New Lung Cancer Treatment and First Next-Gen Companion Diagnostic

Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a patient has a tumor with certain biomarkers, rather than a tumor originating at a certain anatomic site, the agency approved the first companion diagnostic that can detect mutations in multiple genes in a single test.

Read More

AACR In the News

The American Association for Cancer Research (AACR) has appeared in numerous publications lately, showcasing the breadth of our mission to prevent and cure all cancer. News stories have featured scientific research, interviews with AACR leadership, and a first-person account of cancer’s financial toll.

Read More

A Targeted Therapy Next in Line for Biomarker-based Cancer Drug Approval?

recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib (LOXO-101), which showed promising results in adults and children with a variety of cancer types, all of which had one thing in common – fusions involving the gene TRK.

Read More

AACR Welcomes High School Students for National Cancer Research Month

The American Association for Cancer Research (AACR) wrapped up National Cancer Research Month by inviting a group of 50 students from Philadelphia’s George Washington Carver High School for Engineering & Science to the AACR’s Philadelphia headquarters for a morning of conversations about cancer science.

Read More